Charles Schwab Investment Management Inc. trimmed its holdings in shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH - Free Report) TSE: AUP by 10.6% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 665,087 shares of the biotechnology company's stock after selling 78,963 shares during the quarter. Charles Schwab Investment Management Inc. owned approximately 0.46% of Aurinia Pharmaceuticals worth $5,972,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors have also added to or reduced their stakes in AUPH. State Street Corp raised its stake in shares of Aurinia Pharmaceuticals by 2.3% in the third quarter. State Street Corp now owns 2,945,060 shares of the biotechnology company's stock worth $21,587,000 after buying an additional 64,949 shares during the period. Barclays PLC boosted its position in shares of Aurinia Pharmaceuticals by 187.6% in the third quarter. Barclays PLC now owns 219,331 shares of the biotechnology company's stock worth $1,607,000 after purchasing an additional 143,072 shares during the period. Blue Trust Inc. increased its stake in shares of Aurinia Pharmaceuticals by 3,041.4% in the fourth quarter. Blue Trust Inc. now owns 6,377 shares of the biotechnology company's stock worth $57,000 after purchasing an additional 6,174 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. purchased a new position in shares of Aurinia Pharmaceuticals during the 3rd quarter valued at $3,330,000. Finally, Atria Wealth Solutions Inc. purchased a new position in shares of Aurinia Pharmaceuticals during the 4th quarter valued at $135,000. 36.83% of the stock is owned by hedge funds and other institutional investors.
Analysts Set New Price Targets
Separately, StockNews.com raised Aurinia Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a report on Thursday.
Check Out Our Latest Stock Analysis on AUPH
Insider Transactions at Aurinia Pharmaceuticals
In related news, insider Greg Keenan sold 12,239 shares of the firm's stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $8.00, for a total value of $97,912.00. Following the completion of the transaction, the insider now directly owns 161,789 shares of the company's stock, valued at approximately $1,294,312. This trade represents a 7.03 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Joseph M. Miller sold 61,859 shares of the company's stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $8.00, for a total transaction of $494,872.00. Following the sale, the chief financial officer now directly owns 633,515 shares in the company, valued at approximately $5,068,120. The trade was a 8.90 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 343,898 shares of company stock valued at $2,753,094. 4.30% of the stock is currently owned by insiders.
Aurinia Pharmaceuticals Price Performance
Shares of AUPH stock traded down $0.06 during mid-day trading on Thursday, hitting $8.46. The company had a trading volume of 846,003 shares, compared to its average volume of 1,329,009. The company has a debt-to-equity ratio of 0.17, a current ratio of 5.60 and a quick ratio of 5.11. The stock's 50 day moving average price is $8.09 and its 200-day moving average price is $8.02. Aurinia Pharmaceuticals Inc. has a 52-week low of $4.71 and a 52-week high of $10.67. The company has a market capitalization of $1.16 billion, a P/E ratio of -56.40 and a beta of 1.26.
About Aurinia Pharmaceuticals
(
Free Report)
Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.
Further Reading
Before you consider Aurinia Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aurinia Pharmaceuticals wasn't on the list.
While Aurinia Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
